Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 24;12(2):114.
doi: 10.3390/vaccines12020114.

Human Papillomavirus Vaccination in Pediatric, Adolescent, and Young Adult Cancer Survivors-Opportunity to Address Gaps in Cancer Prevention and Survivorship

Melissa A Kluczynski  1 , Elisa M Rodriguez  1 , Cailey S McGillicuddy  1 , Nicolas F Schlecht  1
Affiliations
Review

Human Papillomavirus Vaccination in Pediatric, Adolescent, and Young Adult Cancer Survivors-Opportunity to Address Gaps in Cancer Prevention and Survivorship

Melissa A Kluczynski et al. Vaccines (Basel). .

Abstract

The risks of secondary cancers associated with human papillomavirus (HPV) infection are as much as three times higher for survivors of pediatric, adolescent, and young adult cancer (PYAC) compared to the general population. Despite this, HPV vaccination rates among PYAC survivors remain low. Whereas pediatric oncology providers endorse HPV vaccination of PYAC survivors, many lack the resources or opportunities to intervene. The responsibility of HPV vaccination, therefore, falls to primary care providers and practices. This article provides an overview of the challenges with HPV vaccination that are distinct to PYAC survivors and discusses potential strategies to increase HPV vaccine coverage in this population.

Keywords: cancer survivors; human papillomavirus (HPV) vaccine; pediatric, adolescent, and young adult; secondary cancer prevention; secondary cancers; survivors of childhood cancer; survivorship plan; transition of care.

PubMed Disclaimer

Conflict of interest statement

N.F.S. has served in the past on HPV vaccine scientific advisory boards for Merck, GlaxoSmithKline, and PDS Biotechnology. The remaining authors have no financial or non-financial conflicts of interest.

References

    1. Perkins J.L., Chen Y., Harris A., Diller L., Stovall M., Armstrong G.T., Yasui Y., Robison L.L., Sklar C.A. Infections among long-term survivors of childhood and adolescent cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2014;120:2514–2521. doi: 10.1002/cncr.28763. - DOI - PMC - PubMed
    1. Relling M.V., Rubnitz J.E., Rivera G.K., Boyett J.M., Hancock M.L., Felix C.A., Kun L.E., Walter A.W., Evans W.E., Pui C.-H. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354:34–39. doi: 10.1016/S0140-6736(98)11079-6. - DOI - PubMed
    1. Leone G., Mele L., Pulsoni A., Equitani F., Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84:937–945. - PubMed
    1. Burt L.M., Ying J., Poppe M.M., Suneja G., Gaffney D.K. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast. 2017;35:122–129. doi: 10.1016/j.breast.2017.07.004. - DOI - PubMed
    1. Molina-Montes E., Requena M., Sánchez-Cantalejo E., Fernández M.F., Arroyo-Morales M., Espín J., Arrebola J.P., Sánchez M.-J. Risk of second cancers cancer after a first primary breast cancer: A systematic review and meta-analysis. Gynecol. Oncol. 2015;136:158–171. doi: 10.1016/j.ygyno.2014.10.029. - DOI - PubMed

LinkOut - more resources